About
Desentum Oy is a clinical-stage biopharmaceutical company developing recombinant allergen immunotherapy products aimed at improving the safety, efficacy, and patient experience of allergy treatments for birch pollen, peanut, and cat allergies.
Explore Desentum Oy's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.